A phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
- Resource Type
- Source
- Annals of Oncology. 29:viii89
- Subject
Durvalumab business.industry 030231 tropical medicine Locally advanced Hematology Luminal b 03 medical and health sciences 0302 clinical medicine Immune system Oncology Phase (matter) Cancer research Medicine 030212 general & internal medicine business Triple negative - Language
- ISSN
- 0923-7534